Also trades as: PEARW (NASDAQ) · $vol 0M
PEAR NASDAQ
Pear Therapeutics, Inc.
1W: -43.2%
1M: -70.0%
3M: -99.5%
1Y: -99.9%
$0.03
Last traded 2023-05-23 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$13M
+201.7% ▲
3Y CAGR: -26.9%
Gross Profit
$5M
+540.2% ▲
3Y CAGR: -47.7%
Operating Income
-$123M
-16.7% ▼
Net Income
-$24M
-17.0% ▼
EPS (Diluted)
$-0.17
+5.6% ▲
EBITDA
-$169M
-11.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
| Revenue | $33M | $9M | $4M | $13M |
| YoY Growth | +0.0% | -71.2% | -55.2% | +201.7% |
| Cost of Revenue | $998K | $2M | $5M | $8M |
| Gross Profit | $32M | $8M | -$1M | $5M |
| Gross Margin | 96.9% | 81.7% | -24.4% | 35.5% |
| R&D Expenses | $36M | $28M | $37M | $48M |
| SG&A Expenses | $27M | $56M | $68M | $80M |
| Operating Expenses | $63M | $84M | $105M | $128M |
| Operating Income | -$32M | -$77M | -$106M | -$123M |
| Operating Margin | -97.1% | -816.8% | -2511.5% | -971.7% |
| Interest Expense | $0 | $3M | $0 | $4M |
| Income Before Tax | -$9M | -$97M | -$65M | -$75M |
| Tax Expense | -$22M | $4M | -$45M | -$52M |
| Net Income | $12M | -$101M | -$20M | -$24M |
| Net Margin | 38.1% | -1071.9% | -482.3% | -187.0% |
| EPS (Diluted) | $0.09 | $-0.73 | $-0.18 | $-0.17 |
| EBITDA | -$52M | -$75M | -$152M | -$169M |
| Shares Outstanding | 138M | 138M | 113M | 139M |